NYSE:ABBVBiotechs
AbbVie (ABBV): Valuation Insights After Earnings Beat, Raised Guidance, and New Patent Protection
AbbVie (ABBV) is making headlines after posting strong third quarter earnings, raising its 2025 guidance, and securing additional years of patent protection through a fresh legal settlement with generic rivals.
See our latest analysis for AbbVie.
Momentum is clearly building around AbbVie as bullish news and confident earnings have fueled a 12.5% gain in its share price over the past 90 days, with the stock up an impressive 29.5% year-to-date. When you factor in reinvested dividends, the...